Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Ayal A. Aizer, MD
Study ID
NCT07132190
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Brain Metastases From Extra-cranial Solid Tumors
  • Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
  • Brain Metastases, Adult
  • Brain Tumor - Metastatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV — RADIATION
    Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV

Study Details

The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation treatment. The intent of this shorter time interval is to increase the likelihood that the brain metastases being treated remain fully within the high-dose radiation fields. Participants will be randomized to receive brain-directed stereotactic radiation with a 1mm margin or 0mm margin, have their simulation/radiation planning imaging on the same day that brain-directed stereotactic radiation is delivered, and have repeat simulation/radiation planning scans during the course of treatment if more than 2-3 days have elapsed since the most recent scans.

Key Dates

Start date
Dec 30, 2025
Status verified
Mar 2026
Primary completion
Sep 30, 2028
Completion
Sep 30, 2029

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 0mm PTV
    0mm uncertainty margin
  • Active Comparator: 1mm PTV
    1mm uncertainty margin

Primary Outcome Measure

To assess the percentage of patients that demonstrate tumor beyond the standard planning margin (1.0mm PTV) at the time of stereotactic treatment. [ Time Frame: Diagnostic MRI to MRI on first day of treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's Hospital / Dana-Farber Cancer InstituteBostonMassachusetts02115
Ayal A Aizer, MD, MHS
[email protected]
(617) 732-7560

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital / Dana-Farber Cancer Institute· Boston, MA

Related Studies